Literature DB >> 24441286

The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia.

A Giannoudis1, A Davies1, R J Harris1, C M Lucas1, M Pirmohamed2, R E Clark1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24441286     DOI： 10.1038/leu.2014.38

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.

Authors:  Niove E Jordanides; Heather G Jorgensen; Tessa L Holyoake; Joanne C Mountford
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

2.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

3.  c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells.

Authors:  Antonio Porro; Nunzio Iraci; Simona Soverini; Daniel Diolaiti; Samuele Gherardi; Carolina Terragna; Sandra Durante; Emanuele Valli; Thea Kalebic; Roberto Bernardoni; Chiara Perrod; Michelle Haber; Murray D Norris; Michele Baccarani; Giovanni Martinelli; Giovanni Perini
Journal:  Mol Cancer Res       Date:  2011-06-21       Impact factor: 5.852

4.  Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.

Authors:  Athina Giannoudis; Andrea Davies; Claire M Lucas; Robert J Harris; Munir Pirmohamed; Richard E Clark
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

5.  Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Authors:  Herman Burger; Hans van Tol; Antonius W M Boersma; Mariël Brok; Erik A C Wiemer; Gerrit Stoter; Kees Nooter
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

6.  A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.

Authors:  Sebastian Francis; Claire Lucas; Steven Lane; Lihui Wang; Sarah Watmough; Katy Knight; Jo Bell; Mohammed Kaleel-Rahman; Edwin Lee; David O'Brien; Nauman M Butt; Walid Sadik; Lally De Soysa; Jim R C Seale; Rahuman Salim; Richard E Clark
Journal:  Leuk Res       Date:  2013-04-22       Impact factor: 3.156

7.  Interaction of imatinib with human organic ion carriers.

Authors:  Shuiying Hu; Ryan M Franke; Kelly K Filipski; Chaoxin Hu; Shelley J Orwick; Ernst A de Bruijn; Herman Burger; Sharyn D Baker; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

8.  Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.

Authors:  L Wang; A Giannoudis; S Lane; P Williamson; M Pirmohamed; R E Clark
Journal:  Clin Pharmacol Ther       Date:  2007-06-13       Impact factor: 6.875

9.  Gene expression changes associated with progression and response in chronic myeloid leukemia.

Authors:  Jerald P Radich; Hongyue Dai; Mao Mao; Vivian Oehler; Jan Schelter; Brian Druker; Charles Sawyers; Neil Shah; Wendy Stock; Cheryl L Willman; Stephen Friend; Peter S Linsley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

Review 10.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544
View more
  11 in total

Review 1.  Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.

Authors:  Michele Baccarani; Robert Peter Gale
Journal:  Leukemia       Date:  2021-05-17       Impact factor: 11.528

Review 2.  Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.

Authors:  Marjan Yaghmaie; Cecilia Cs Yeung
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

3.  The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Authors:  L N Eadie; P Dang; V A Saunders; D T Yeung; M P Osborn; A P Grigg; T P Hughes; D L White
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

4.  Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.

Authors:  Xuejun Liu; Dongwei Yao; Cheng Liu; Yunjian Cao; Qiurong Yang; Zhichao Sun; Duo Liu
Journal:  Tumour Biol       Date:  2016-01-05

Review 5.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

Review 6.  Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Authors:  Ami B Patel; Thomas O'Hare; Michael W Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2017-08       Impact factor: 3.722

7.  Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.

Authors:  Alessandra Trojani; Ester Pungolino; Alessandra Dal Molin; Milena Lodola; Giuseppe Rossi; Mariella D'Adda; Alessandra Perego; Chiara Elena; Mauro Turrini; Lorenza Borin; Cristina Bucelli; Simona Malato; Maria Cristina Carraro; Francesco Spina; Maria Luisa Latargia; Salvatore Artale; Pierangelo Spedini; Michela Anghilieri; Barbara Di Camillo; Giacomo Baruzzo; Gabriella De Canal; Alessandra Iurlo; Enrica Morra; Roberto Cairoli
Journal:  PLoS One       Date:  2019-07-18       Impact factor: 3.240

8.  ABCC3 Expressed by CD56dim CD16+ NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy.

Authors:  Serena Pellegatta; Natalia Di Ianni; Sara Pessina; Rosina Paterra; Elena Anghileri; Marica Eoli; Gaetano Finocchiaro
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

9.  ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells.

Authors:  Laura N Eadie; Phuong Dang; Jarrad M Goyne; Timothy P Hughes; Deborah L White
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

10.  Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.

Authors:  Bharathi M Rajamani; Esther Sathya Bama Benjamin; Aby Abraham; Sukanya Ganesan; Kavitha M Lakshmi; Senthamizhselvi Anandan; Sreeja Karathedath; Savitha Varatharajan; Ezhilpavai Mohanan; Nancy Beryl Janet; Vivi M Srivastava; Shaji Ramachandran Velayudhan; Uday P Kulkarni; Anup J Devasia; N A Fouzia; Anu Korula; Biju George; Alok Srivastava; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.